Literature DB >> 23481262

Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?

Carmen Berasain.   

Abstract

Entities:  

Keywords:  Drug Resistance; Gene Targeting; Hepatocellular Carcinoma; Liver; Molecular Carcinogenesis

Mesh：

Substances：

Year:  2013        PMID： 23481262     DOI： 10.1136/gutjnl-2013-304564

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  38 in total

1.  Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.

Authors:  Bernhard Gillissen; Anja Richter; Antje Richter; Robert Preissner; Klaus Schulze-Osthoff; Frank Essmann; Peter T Daniel
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

2.  Recapitulation of pharmacogenomic data reveals that invalidation of SULF2 enhance sorafenib susceptibility in liver cancer.

Authors:  Sarah Yoon; Eun-Ju Lee; Ji-Hye Choi; Taek Chung; Do Young Kim; Jong-Yeop Im; Myung-Ho Bae; Jung-Hee Kwon; Hyuk-Hoon Kim; Hyung Chul Kim; Young Nyun Park; Hee-Jung Wang; Hyun Goo Woo
Journal:  Oncogene       Date:  2018-05-03       Impact factor: 9.867

3.  Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma.

Authors:  Feng Liu; Xiaofeng Dong; Hong Lv; Peng Xiu; Tao Li; Fuhai Wang; Zongzhen Xu; Jie Li
Journal:  Oncol Lett       Date:  2015-06-03       Impact factor: 2.967

4.  Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.

Authors:  Yi Shi; Aimin Huang
Journal:  Tumour Biol       Date:  2015-05-31

5.  PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy.

Authors:  Jian-Feng Zheng; Shaozhong He; Zongyue Zeng; Xinqi Gu; Lei Cai; Guangying Qi
Journal:  Mol Ther       Date:  2019-07-05       Impact factor: 11.454

6.  In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.

Authors:  Ramona Rudalska; Daniel Dauch; Thomas Longerich; Katherine McJunkin; Torsten Wuestefeld; Tae-Won Kang; Anja Hohmeyer; Marina Pesic; Josef Leibold; Anne von Thun; Peter Schirmacher; Johannes Zuber; Karl-Heinz Weiss; Scott Powers; Nisar P Malek; Martin Eilers; Bence Sipos; Scott W Lowe; Robert Geffers; Stefan Laufer; Lars Zender
Journal:  Nat Med       Date:  2014-09-14       Impact factor: 53.440

7.  Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.

Authors:  Elizabeth A Kuczynski; Christina R Lee; Shan Man; Eric Chen; Robert S Kerbel
Journal:  Cancer Res       Date:  2015-04-23       Impact factor: 12.701

8.  YAP promotes sorafenib resistance in hepatocellular carcinoma by upregulating survivin.

Authors:  Ting Sun; Wenhao Mao; Hui Peng; Qi Wang; Lin Jiao
Journal:  Cell Oncol (Dordr)       Date:  2021-03-03       Impact factor: 6.730

9.  Poly(vinyl alcohol)/gelatin Hydrogels Cultured with HepG2 Cells as a 3D Model of Hepatocellular Carcinoma: A Morphological Study.

Authors:  Stefania Moscato; Francesca Ronca; Daniela Campani; Serena Danti
Journal:  J Funct Biomater       Date:  2015-01-13

10.  MicroRNA-92b augments sorafenib resistance in hepatocellular carcinoma via targeting PTEN to activate PI3K/AKT/mTOR signaling.

Authors:  Zhouyang Cheng; Qingfeng Ni; Lei Qin; Yang Shi
Journal:  Braz J Med Biol Res       Date:  2021-05-31       Impact factor: 2.590
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.